A5042264136- Hemoglobinopathies and Related Disorders
- Blood groups and transfusion
- Blood disorders and treatments
- Erythrocyte Function and Pathophysiology
- Acute Myeloid Leukemia Research
- CAR-T cell therapy research
- Hematopoietic Stem Cell Transplantation
- Cutaneous lymphoproliferative disorders research
- Complement system in diseases
- Cancer-related gene regulation
- Renal Diseases and Glomerulopathies
- Erythropoietin and Anemia Treatment
- Geological formations and processes
- Immunodeficiency and Autoimmune Disorders
- Hematological disorders and diagnostics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- RNA modifications and cancer
- Karst Systems and Hydrogeology
- Groundwater flow and contamination studies
- Blood transfusion and management
- Kruppel-like factors research
- Epigenetics and DNA Methylation
- Chronic Myeloid Leukemia Treatments
- 3D Surveying and Cultural Heritage
- Autoimmune Bullous Skin Diseases
University of Milan
2022-2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2022-2025
IRCCS Policlinico San Donato
2023
Ospedale Maggiore
2022
Istituti di Ricovero e Cura a Carattere Scientifico
2022
Institute of Environmental Geology and Geoengineering
2015
ABSTRACT We retrospectively analyzed a large international cohort of 1113 patients with aplastic anemia to evaluate treatment choice and outcome in elderly as compared younger population. Overall, 319 (29%) were > 60 years old at diagnosis (60–64 ( n = 85), 106 65–69 106), 128 70 128)). Elderly showed more severe thrombocytopenia onset significantly lower overall response (complete plus partial) first‐line therapy 6 months (47% vs. 65%, p < 0.0001), irrespective modality (ATG or CyA...
Abstract Complement inhibitors are the mainstay of paroxysmal nocturnal hemoglobinuria (PNH) treatment. The anti‐C5 monoclonal antibody eculizumab was first treatment to improve hemolysis, thrombotic risk, and survival in PNH although at price a life‐long intravenous fortnightly drug. Additionally, suboptimal response may occur up 2/3 patients with persistent anemia due incomplete control intravascular development upstream C3‐mediated extravascular hemolysis (EVH), or concomitant bone marrow...
Breakthrough hemolysis (BTH) is the hemolytic exacerbation occurring in a patient with paroxysmal nocturnal hemoglobinuria (PNH) on treatment anti-complement therapies. In this review article we analysed definition, frequency and severity of BTH events across phase 3 clinical trials terminal (anti-C5 ravulizumab crovalimab) complement inhibitors upstream C5 (anti-C3 pegcetacoplan, alternative-pathway iptacopan danicopan), as well from real-world reports. Furthermore, reviewed impact various...
Abstract Background Autoimmune hemolytic anemia (AIHA) may be associated with transfusion reactions and risk of alloimmunization. Objectives To evaluate the policy rate alloimmunization its clinical significance in AIHA. Methods Data from 305 AIHA patients followed at a reference hematologic Center Milan, Italy 1997 to 2022 were retrospectively/prospectively collected (NCT05931718). Results Overall, 33% required transfusions response 83% eight (7%), none hemolytic. Alloantibodies detected...
Patients with myelodysplastic syndromes and ring sideroblasts (MDS RS) are clinically characterized by severe anemia transfusion need. Erythropoiesis-stimulating agents (ESAs), which stimulate hemoglobin production early maturation of erythroid precursors, effective only in a portion patients for limited time. Luspatercept, an inhibitor the TGF-beta pathway, is beneficial unblocking late-stage erythropoiesis has been approved MDS RS failing or not-candidate to ESAs. ESAs and/or luspatercept...
The boundaries between myelodysplastic syndromes (MDS) and immune-mediated cytopenias are often difficult to establish both conditions may benefit from immunosuppressive therapy. optimal timing doses of immunosuppressants largely unknown.We systematically evaluated a retrospective cohort 79 patients with low-risk MDS tested for anti-erythrocyte or anti-platelet autoantibodies assess their frequency the efficacy immunosuppression, particularly steroids.We found autoantibody positivity in 43%...
More than half of patients with paroxysmal nocturnal hemoglobinuria (PNH) treated complement fraction C5 inhibitors experience residual anemia and hemolysis. This is partly due to the persistent activation cascade upstream C5, resulting in C3 deposition on PNH erythrocytes extravascular hemolysis reticuloendothelial system. Pegcetacoplan first proximal inhibitor be approved for basing favorable efficacy safety data both naïve eculizumab PNH. Here we report Italian patient pegcetacoplan a...
Topic: 31. Transfusion medicine Background: Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disease, ranging from mild to very severe forms; the latter may present acutely require transfusion support. There are several concerns regarding risk of reactions alloimmunization, reported in about 1/3 cases historical series. However, data on their clinical impact lacking, especially considering evolving blood selection strategies last decades. Aims: To evaluate policy rate...
Through the establishment of an educational laboratory, Institute Environmental Geology and Geoengineering National Research Council (CNR IGAG) intends to provide students lower upper secondary schools with understanding concept seismic hydrogeological hazards risks, disseminate knowledge on mitigation measures aimed at reducing impact disasters cultural heritages (e.g., earthquakes floods). A prestigious case study addressed in this context is offered by city Rome central archaeological...